Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
PMID: 29274766

Abstract

BACKGROUND: The use of therapeutic drug monitoring has been proposed as a useful tool in the management of patients with loss of response to biological therapy in patients with inflammatory bowel disease.

Authors

  • Giorgia Bodini
    Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. Electronic address: giorgia.bodini@edu.unige.it.
  • Edoardo G Giannini
    Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Vincenzo Savarino
    Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Lorenzo Del Nero
    Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Sara Lo Pumo
    Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Matteo Brunacci
    Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Nicola De Bortoli
    Gastroenterology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy.
  • Anjali Jain
    Department of Research and Development, Prometheus Laboratories Inc., San Diego, CA, USA.
  • Salvatore Tolone
    Department of Surgery, Second University of Naples, Naples, Italy.
  • Edoardo Savarino
    Gastroenterolgy Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

Keywords

External Resources

Popular Topics
Recent Journals